Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | LCK | P06239 | 3/20 | 0.57 |
| ▸ | TEK | Q02763 | 1/20 | 0.57 |
| ▸ | USP36 | Q9P275 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.54 |
| ▸ | KIT | P10721 | 2/20 | 0.54 |
| ▸ | SRC | P12931 | 2/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.54 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.54 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.53 |
| ▸ | CCNC | P24863 | 1/20 | 0.52 |
| ▸ | CDK8 | P49336 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31314816 | 1.00 | MEN1 (0.65) | MEN1KMT2ATSHRMAPTLCK | |
| SCHEMBL17936093 | 0.85 | MAPT (0.74) | MEN1KMT2ATSHRMAPTLCK | |
| SCHEMBL17818404 | 0.83 | MAPT (0.70) | MEN1KMT2ATSHRMAPTLCK | |
| SCHEMBL2974953 | 0.82 | LCK (0.81) | MEN1KMT2ATSHRMAPTLCK | |
| SCHEMBL15238766 | 0.81 | MEN1 (0.75) | MEN1KMT2ATSHRMAPTLCK | |
| SCHEMBL16782133 | 0.80 | KDR (0.67) | MEN1KMT2ATSHRMAPTLCK | |
| SCHEMBL17818365 | 0.80 | MAPT (0.66) | MEN1KMT2AMAPTRXFP1KCNK3 | |
| SCHEMBL22384740 | 0.79 | LCK (0.67) | MEN1KMT2ATSHRMAPTLCK | |
| SCHEMBL31314801 | 0.79 | KDR (0.53) | MEN1KMT2AMAPTKITKDR | |
| SCHEMBL26131577 | 0.79 | KDR (0.53) | MEN1KMT2AMAPTKITKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243203-A1 | NICOTINAMIDE- AND BENZAMIDE-BASED COMPOUNDS, CONJUGATES, AND COMPOSITIONS AS INHIBITORS OF TRANSLATIONAL- AND TRANSCRIPTIONAL-RELATED KINASES | PURDUE RESEARCH FOUNDATION | 2025-07-31 | — | — | US | disclosed |
| EP-4504174-A2 | NICOTINAMIDE- AND BENZAMIDE-BASED COMPOUNDS, CONJUGATES, AND COMPOSITIONS AS INHIBITORS OF TRANSLATIONAL- AND TRANSCRIPTIONAL-RELATED KINASES | Purdue Research Foundation (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2023196930-A2 | NICOTINAMIDE- AND BENZAMIDE-BASED COMPOUNDS, CONJUGATES, AND COMPOSITIONS AS INHIBITORS OF TRANSLATIONAL- AND TRANSCRIPTIONAL-RELATED KINASES | PURDUE RESEARCH FOUNDATION (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196930-A2 | NICOTINAMIDE- AND BENZAMIDE-BASED COMPOUNDS, CONJUGATES, AND COMPOSITIONS AS INHIBITORS OF TRANSLATIONAL- AND TRANSCRIPTIONAL-RELATED KINASES | PURDUE RESEARCH FOUNDATION (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230219934-A1 | 2,3-DISUBSTITUTED PYRIDO[3,4-B]PYRAZINE-CONTAINING COMPOUNDS AS KINASE INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230219934-A1 | 2,3-DISUBSTITUTED PYRIDO[3,4-B]PYRAZINE-CONTAINING COMPOUNDS AS KINASE INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230219934-A1 | 2,3-DISUBSTITUTED PYRIDO[3,4-B]PYRAZINE-CONTAINING COMPOUNDS AS KINASE INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2023-07-13 | — | — | US | disclosed |
| WO-2021262915-A1 | 2,3-DISUBSTITUTED PYRIDO[3,4-B]PYRAZINE-CONTAINING COMPOUNDS AS KINASE INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2021-12-30 | — | — | WO | disclosed |
| EP-3284738-B1 | 5-AROMATIC ALKYNYL SUBSTITUTED BENZAMIDE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2020-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219934-A1 | 2,3-DISUBSTITUTED PYRIDO[3,4-B]PYRAZINE-CONTAINING COMPOUNDS AS KINASE INHIBITORS | MAP3K2, MAP4K2, MAP3K5 | MEN1 2753/4885KMT2A 797/4885TSHR 2415/4885 |
| US-20250243203-A1 | NICOTINAMIDE- AND BENZAMIDE-BASED COMPOUNDS, CONJUGATES, AND COMPOSITIONS AS INHIBITORS OF TRANSLATIONAL- AND TRANSCRIPTIONAL-RELATED KINASES | NADK, NAMPT, NNMT | MEN1 2850/4885KMT2A 349/4885TSHR 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.